Fermenta Biotech Ltd

As of June 30, 2026, Fermenta Biotech Ltd carries a market capitalization of 9.93B, placing it among publicly traded companies globally. Its enterprise value stands at 9.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fermenta Biotech Ltd's next confirmed earnings release is scheduled for November 14, 2026.

As of June 30, 2026, Fermenta Biotech Ltd has 27.92M shares outstanding.

As of June 30, 2026, Fermenta Biotech Ltd trades at a trailing price-to-earnings ratio of 17.01.

As of June 30, 2026, Fermenta Biotech Ltd trades at an EV/EBITDA multiple of 10.29 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.93B versus a market cap of 9.93B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.85M in revenue per employee across its workforce of 873.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Fermenta Biotech Ltd recorded 242.81M in income tax expense. That works out to an effective tax rate of 29.44, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 824.65M, leaving 604.86M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Fermenta Biotech Ltd generated 5.11B in revenue and converted that into 604.86M in net income, yielding earnings per share of 19.93. EBITDA reached 965.29M, while operating income came in at 685.73M.

Over the twelve months ended June 30, 2026, Fermenta Biotech Ltd posted a gross margin of 64.39, reflecting its pricing power and cost economics. The operating margin of 13.42 and net profit margin of 11.84 provide insight into operational efficiency.

Fermenta Biotech Ltd's most recent stock split took place on February 13, 2020 with a 1:3 split ratio.